<DOC>
	<DOCNO>NCT01520649</DOCNO>
	<brief_summary>This Randomized , Double-Blind , Placebo-Controlled , Multiple-Dose Escalation depress human subject study .</brief_summary>
	<brief_title>Multiple-Dose Pharmacokinetics ( PK ) , Pharmacodynamic ( PD ) Effect NSI-189 Phosphate Depression Patient Subjects</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>1 . Patient ability understand purpose risk study provide sign date informed consent , authorize use protect health information accordance national local patient privacy regulation . 2 . Males females 18 60 year age , inclusive , time informed consent . 3 . Diagnosis major depressive disorder , recurrent , per DSMIVTR criterion confirm SCIDCT . Their major depressive episode must confirm via SCID mood module interview administer remote , independent raters . Note : Both patient treat antidepressant patient antidepressant history take antidepressant permit study . 4 . MontgomeryAsberg Depression Scale ( MADRS ) score 15 30 , inclusive , Screening baseline . 5 . The following applies female patient : Nonpregnant , nonlactating female childbearing potential agree use medically acceptable form birth control ( hormonal contraception , abstinence , diaphragm spermicide , condom spermicide , intrauterine device ) Screening endofstudy . 6 . The following applies male subject :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Neurogenesis</keyword>
	<keyword>hippocampal stem cell</keyword>
	<keyword>depression</keyword>
	<keyword>stroke</keyword>
</DOC>